about
TNF-alpha inhibitors for psoriatic arthritisMeasures of psoriatic arthritis: Tender and Swollen Joint Assessment, Psoriasis Area and Severity Index (PASI), Nail Psoriasis Severity Index (NAPSI), Modified Nail Psoriasis Severity Index (mNAPSI), Mander/Newcastle Enthesitis Index (MEI), Leeds EnClinical Tools to Assess and Monitor SpondyloarthritisClinical outcomes in psoriatic arthritis: A systematic literature reviewSubclinical enthesopathy in patients with psoriasis and its association with other disease parameters: a power Doppler ultrasonographic studyEnteropathic arthritis in Brazil: data from the Brazilian Registry of Spondyloarthritis.First signs and symptoms of spondyloarthritis--data from an inception cohort with a disease course of two years or less (REGISPONSER-Early)Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phasEffectiveness of adalimumab in treating patients with ankylosing spondylitis associated with enthesitis and peripheral arthritis.Drug retention rates and treatment discontinuation among anti-TNF-α agents in psoriatic arthritis and ankylosing spondylitis in clinical practice.Effectiveness and safety of adalimumab in patients with ankylosing spondylitis or psoriatic arthritis and history of anti-tumor necrosis factor therapy.Predictors of functional deterioration in Chinese patients with psoriatic arthritis: a longitudinal studyThe TICOPA protocol (TIght COntrol of Psoriatic Arthritis): a randomised controlled trial to compare intensive management versus standard care in early psoriatic arthritisPatient-reported outcomes and the association with clinical response in patients with active psoriatic arthritis treated with golimumab: findings through 2 years of a phase III, multicenter, randomized, double-blind, placebo-controlled trial.Ultrasound features of shoulder involvement in patients with ankylosing spondylitis: a case-control studyRandomized controlled trial of adalimumab in patients with nonpsoriatic peripheral spondyloarthritis.Effects of etanercept versus sulfasalazine in early axial spondyloarthritis on active inflammatory lesions as detected by whole-body MRI (ESTHER): a 48-week randomised controlled trialPsoriatic arthritis assessment tools in clinical trials.Clinical and ultrasound examination of the leeds enthesitis index in psoriatic arthritis and rheumatoid arthritis.A sonographic enthesitic index of lower limbs is a valuable tool in the assessment of ankylosing spondylitisGuideline for anti-TNF-alpha therapy in psoriatic arthritis.Anterior chest wall inflammation by whole-body magnetic resonance imaging in patients with spondyloarthritis: lack of association between clinical and imaging findings in a cross-sectional studyDiagnositic value of pelvic enthesitis on MRI of the sacroiliac joints in enthesitis related arthritis.Management and evaluation of extra-articular manifestations in spondyloarthritisMeasuring disease activity in psoriatic arthritis.Methotrexate Efficacy in the Tight Control in Psoriatic Arthritis Study.A randomized, double-blind, placebo-controlled, sixteen-week study of subcutaneous golimumab in patients with active nonradiographic axial spondyloarthritisEfficacy and safety of adalimumab in patients with non-radiographic axial spondyloarthritis: results of a randomised placebo-controlled trial (ABILITY-1).The psoriatic arthritis cost evaluation study: a cost-of-illness study on tumour necrosis factor inhibitors in psoriatic arthritis patients with inadequate response to conventional therapy.Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis and current skin involvement: a phase III, randomised, controlled trial (PALACE 3)Clinical potential of apremilast in the treatment of psoriatic arthritisEffect of tight control of inflammation in early psoriatic arthritis (TICOPA): a UK multicentre, open-label, randomised controlled trial.Adalimumab effectiveness for the treatment of ankylosing spondylitis is maintained for up to 2 years: long-term results from the ATLAS trial.Clinical efficacy, radiographic and safety findings through 2 years of golimumab treatment in patients with active psoriatic arthritis: results from a long-term extension of the randomised, placebo-controlled GO-REVEAL study.A Randomized, Double-Blind, Placebo-Controlled Multicenter Study of Adalimumab in Pediatric Patients With Enthesitis-Related Arthritis.Low-dose modified-release prednisone in axial spondyloarthritis: 3-month efficacy and tolerability.Inflammatory arthritis: an overview for primary care physicians.Evaluation and Treatment of Enthesitis-Related Arthritis.Treating spondyloarthritis, including ankylosing spondylitis and psoriatic arthritis, to target: recommendations of an international task force.Gender differences among patients with primary ankylosing spondylitis and spondylitis associated with psoriasis and inflammatory bowel disease in an iberoamerican spondyloarthritis cohort.
P2860
Q24240905-3AC3623F-7F9A-4F37-930F-C464D73F6899Q26862017-EC23C41A-239A-43A2-B0F9-42992ED9B0CEQ26866120-6284E07A-5F2A-425B-9A39-C9789125A796Q26995307-B071ED0E-6614-4222-90C6-8273C6D55A6EQ30361133-3ECEA738-86F2-4B98-863C-B0D38908A542Q30745189-D8A1C035-0F23-405B-A464-EEAF04F4782CQ33408102-FFB4E31D-1E31-4C22-B7EA-DE7F8788F31BQ33659249-642E04B1-70FE-4EB7-95A5-0995951877F6Q33923298-471FC0BE-FCBD-4850-9F34-FC45A11000A3Q33993099-A5B841E3-F7B7-4378-BC1A-24911E45FC91Q34027624-946BD962-F67E-482D-B186-216E09A45E1BQ34174214-DF484DE8-27DF-4ACC-AC7E-A0CB42158DEAQ34630959-B25D0E90-80D6-4E9E-B499-A9F79B2CE19DQ34803148-CB199FE8-1F0B-4D04-8C84-F48962BB2E3AQ34993041-FF1F1D0B-2EB9-443F-9046-90FF733F95E4Q35535807-549F2AC9-30A7-468A-BE99-39F08C2660B7Q35537104-F37265E6-DF37-4A66-B721-D97E60470265Q35579462-C2F1DCE7-96D3-49AC-A392-01C5C96FF134Q35687813-115D8721-C5BD-4FFC-BE07-8F2080F96B01Q35953484-0576C7E3-0256-4FA6-861D-46C8033737CDQ36032569-0EEAF679-96C4-4295-B933-C2298EDDBECAQ36084884-908D06BA-F5CF-41C4-A0C4-111264B0E696Q36270343-490EDEFB-BEE8-4CE2-ABAA-2F5E12BDA4F1Q36439889-0248F2B5-A697-413A-B884-C0856230EACFQ36520126-FF445383-BEC2-457E-8B91-1C32F1ACA642Q36542790-A470C1F8-CAB7-4EAA-8BEC-6EF8948BB9F8Q36584217-A77447FD-50B0-45DE-ACA3-FA5EDE34E0DBQ36876679-4909EDA2-9707-45A4-88E2-82A66F7CC2E1Q36940942-CABE8676-1C44-420F-8A67-6AC122AA0D06Q36968787-9F93851F-CC18-41BD-9326-553A391720F0Q37031662-81FC9E0D-38A2-4D77-A924-6B90A466D32FQ37036355-9C263701-EDBB-4700-9279-CBA17EA66D36Q37172795-CA801050-E413-4C11-B1E5-04217C0FF2A3Q37267600-952A4DAD-8B46-45F7-9A97-BEB5CB381DEDQ37325983-69F95518-4793-4B82-AEBA-843420C9AF10Q37423289-2881602C-B70D-448A-AC98-536A5D323854Q37427257-DDB81037-DCCF-4E6A-B418-A113965BCFFDQ37438552-AC291403-8E14-45F7-892B-AF2EC1679A55Q37465518-EA4F7651-1870-46E0-9AF1-E4C2EA468788Q37530561-1F05E7D3-9F51-4C17-BC93-8E471E8C51FB
P2860
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
2003年论文
@zh
2003年论文
@zh-cn
name
Assessment of enthesitis in ankylosing spondylitis.
@ast
Assessment of enthesitis in ankylosing spondylitis.
@en
type
label
Assessment of enthesitis in ankylosing spondylitis.
@ast
Assessment of enthesitis in ankylosing spondylitis.
@en
prefLabel
Assessment of enthesitis in ankylosing spondylitis.
@ast
Assessment of enthesitis in ankylosing spondylitis.
@en
P2093
P2860
P356
P1476
Assessment of enthesitis in ankylosing spondylitis.
@en
P2093
Dougados M
Heuft-Dorenbosch L
Mielants H
Spoorenberg A
van Tubergen A
van der Heijde D
van ver Tempel H
P2860
P304
P356
10.1136/ARD.62.2.127
P407
P577
2003-02-01T00:00:00Z